<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04911361</url>
  </required_header>
  <id_info>
    <org_study_id>DEPOT 1911 OTX</org_study_id>
    <nct_id>NCT04911361</nct_id>
  </id_info>
  <brief_title>The DEPOT Study (Dry Eye Prescription Options for Therapy)</brief_title>
  <official_title>The DEPOT Study (Dry Eye Prescription Options for Therapy): A Randomized Controlled Clinical Trial Assessing the Efficacy and Safety of DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert, When Placed Within the Lower Eye Eyelid Canaliculus in Comparison to Topical Loteprednol Suspension for the Treatment of Episodic Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research Insight LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Research Insight LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing DEXTENZA efficacy and safety when placed within the lower eyelid canaliculus for&#xD;
      dry eye flares in comparison to topical loteprednol suspension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DEPOT Study (Dry Eye Prescription Options for Therapy): A randomized controlled clinical&#xD;
      trial assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg&#xD;
      insert, when placed within the lower eye eyelid canaliculus in comparison to topical&#xD;
      loteprednol suspension for the treatment of episodic dry eye.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2021</start_date>
  <completion_date type="Anticipated">August 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 26, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a multicenter, prospective, randomized controlled, open label study of the efficacy of relieving both signs and symptoms of dry eye syndrome in patients with exacerbations of this disease. Patients will be randomized to receive treatment of either Dextenza or loteprednol etabonate 0.5% suspension QID for 2 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine effect of dexamethasone insert</measure>
    <time_frame>2 Weeks</time_frame>
    <description>SPEED score at Baseline and Week 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the effect of dexamethasone insert</measure>
    <time_frame>4 Weeks</time_frame>
    <description>The difference in SPEED questionnaire scores before and 4 weeks after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in conjunctival hyperemia</measure>
    <time_frame>4 weeks</time_frame>
    <description>Slit exam to determine ocular hyperemia using the Schulze Scale before and 4 weeks after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in tear break up time (TBUT) before and after treatment</measure>
    <time_frame>4 Weeks</time_frame>
    <description>Reduced tear break up time (TBUT) â‰¤ 10 seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in corneal staining before and after treament</measure>
    <time_frame>4 Weeks</time_frame>
    <description>The presence of central or inferior staining defined by the Oxford Scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety outcome measure</measure>
    <time_frame>At baseline, 2 weeks, and 4 weeks</time_frame>
    <description>Intraocular pressure at Baseline, Week 2 &amp; 4</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Topical loteprednol suspension in both eyes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 subjects will be randomized to receive treatment loteprednol etabonate 0.5% suspension QID for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lower eyelid canaliculi DEXTENZA insertion (study group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 subjects will be randomized to receive treatment of OTX-DED</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Patients will be randomized for either topical loteprednol suspension in both eyes (control group) or lower eyelid canaliculi DEXTENZA insertion (study group)</description>
    <arm_group_label>Lower eyelid canaliculi DEXTENZA insertion (study group)</arm_group_label>
    <arm_group_label>Topical loteprednol suspension in both eyes</arm_group_label>
    <other_name>DEXTENZA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 years and older&#xD;
&#xD;
          -  Patients willing to take an electronic survey about their tolerability of either study&#xD;
             medication.&#xD;
&#xD;
          -  Patients with a recent exacerbation of dry eye characterized by ocular surface&#xD;
             discomfort.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active, systemic or local disease condition other than DES that causes clinically&#xD;
             significant ocular surface irritation that could interfere with the evaluation and&#xD;
             treatment of dry eye.&#xD;
&#xD;
          -  Any of the following ocular (eye or eyelid) conditions in either eye within 1 Months&#xD;
             prior to the enrollment visit:&#xD;
&#xD;
               -  Ocular surgery (e.g., intraocular, oculoplastic, corneal or refractive surgery&#xD;
                  procedure)&#xD;
&#xD;
               -  Clinically significant ocular trauma.&#xD;
&#xD;
               -  Active ocular Herpes simplex or Herpes zoster (eye or eyelid) infection.&#xD;
&#xD;
               -  Ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis,&#xD;
                  conjunctivitis)&#xD;
&#xD;
               -  Ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal&#xD;
                  infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids&#xD;
                  including hordeolum/stye)&#xD;
&#xD;
          -  Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis&#xD;
&#xD;
          -  Eyelid abnormalities that significantly affect lid function (e.g., entropion,&#xD;
             ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe&#xD;
             ptosis)&#xD;
&#xD;
          -  Ocular surface abnormality that may compromise corneal integrity (e.g., prior chemical&#xD;
             burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal&#xD;
             fluorescein staining, or map dot fingerprint dystrophy)&#xD;
&#xD;
          -  Participation in another ophthalmic clinical trial involving a therapeutic drug or&#xD;
             device within 30 days prior to the distribution of the survey&#xD;
&#xD;
          -  Participation in this trial in the same patient's fellow eye.&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding or who may become pregnant during&#xD;
             participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Hovanesian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Insight LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leslie Lemieux</last_name>
    <phone>951-388-4422</phone>
    <email>research@researchinsightca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inland Eye Specialists</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92545</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jazmin Ponce</last_name>
      <phone>951-492-4205</phone>
    </contact>
    <investigator>
      <last_name>Robert Sorenson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harvard Eye Associates</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lannhi Nguyen</last_name>
      <phone>949-900-5248</phone>
    </contact>
    <investigator>
      <last_name>John Hovanesian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Wiemers</last_name>
      <phone>314-966-3377</phone>
    </contact>
    <investigator>
      <last_name>Gregg Berdy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dextenza.com/wp-content/uploads/2019/06/NDA-208742-S001-Dextenza-labeling-19Jun19.pdf</url>
    <description>DEXTENZA (dexamethasone insert) Prescribing Information, Ocular Therapeutix,Inc.2019</description>
  </link>
  <reference>
    <citation>Tyson SL, Bafna S, Gira JP, Goldberg DF, Jones JJ, Jones MP, Kim JK, Martel JM, Nordlund ML, Piovanetti-Perez IK, Singh IP, Metzinger JL, Mulani D, Sane S, Talamo JH, Goldstein MH; Dextenza Study Group. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2019 Feb;45(2):204-212. doi: 10.1016/j.jcrs.2018.09.023. Epub 2018 Oct 24. Erratum in: J Cataract Refract Surg. 2019 Jun;45(6):895.</citation>
    <PMID>30367938</PMID>
  </reference>
  <reference>
    <citation>Walters TR, et al. Efficacy and Safety of Sustained Release Dexamethasone for the Treatment of Ocular Pain and Inflammation after Cataract Surgery: Results from Two Phase 3 Studies. J Clin Exp Ophthalmol. 2016; 7(4):</citation>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD results will be shared in publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

